Clinical Trial Update: A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is recruiting to evaluate AAV2-BDNF gene therapy for early Alzheimer's disease and mild cognitive impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• AAV2-BDNF gene therapy (AAV2-BDNF gene therapy)

Snippet

Sponsor: Mark Tuszynski | Conditions: Alzheimer's Disease, Mild Cognitive Impairment | Phase 1 | Status: RECRUITING